ATAI Life Sciences AG Amends COMPASS Pathways Stake Filing
Ticker: ATAI · Form: SC 13D/A · Filed: Sep 27, 2024 · CIK: 1840904
| Field | Detail |
|---|---|
| Company | Atai Life Sciences N.V. (ATAI) |
| Form Type | SC 13D/A |
| Filed Date | Sep 27, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $6.05 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 13D-filing, ownership-change, pharmaceuticals
Related Tickers: CMPS
TL;DR
ATAI Life Sciences AG updated its filing on COMPASS Pathways, watch for ownership changes.
AI Summary
ATAI Life Sciences AG, through its subsidiary ATAI Life Sciences N.V., has filed an amendment (Amendment No. 3) to its Schedule 13D concerning its holdings in COMPASS Pathways plc. The filing, dated September 27, 2024, indicates a change in the reporting person's beneficial ownership of COMPASS Pathways plc ordinary shares. The specific details of the change in ownership percentage or number of shares are not explicitly stated in the provided text, but the amendment signifies an update to their previous filings.
Why It Matters
This filing updates the market on ATAI Life Sciences' significant stake in COMPASS Pathways, a key player in the mental health innovation space, potentially signaling strategic shifts or ongoing investment.
Risk Assessment
Risk Level: medium — Schedule 13D filings often indicate significant investor activity, which can lead to stock price volatility and strategic corporate actions.
Key Players & Entities
- ATAI Life Sciences AG (company) — Reporting Person
- ATAI Life Sciences N.V. (company) — Subsidiary of Reporting Person
- COMPASS Pathways plc (company) — Issuer of Securities
- Ryan Barrett (person) — Contact Person for ATAI Life Sciences AG
FAQ
What specific changes were made in Amendment No. 3 to the Schedule 13D filing?
The filing indicates a change in the reporting person's beneficial ownership of COMPASS Pathways plc ordinary shares, but the exact details of the change are not provided in the excerpt.
Who is the primary filer for this Schedule 13D/A?
ATAI Life Sciences AG is the primary filer, with Ryan Barrett listed as a contact person.
What is the CUSIP number for COMPASS Pathways plc ordinary shares?
The CUSIP number for COMPASS Pathways plc ordinary shares is 20451W101.
What is the business address of ATAI Life Sciences AG as listed in the filing?
The business address for ATAI Life Sciences AG is Wallstraße 16, 10179 Berlin, Germany.
What is the SIC code for COMPASS Pathways plc?
The Standard Industrial Classification (SIC) code for COMPASS Pathways plc is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 875 words · 4 min read · ~3 pages · Grade level 13.2 · Accepted 2024-09-27 19:56:26
Key Financial Figures
- $6.05 — 2,660,000 Ordinary Shares at a price of $6.05 per share in an open market transaction
Filing Documents
- ef20036450_sc13da.htm (SC 13D/A) — 66KB
- 0001140361-24-042244.txt ( ) — 67KB
(a) – (b) of the Schedule 13D is amended and restated in its entirety by inserting the following information
Item 5(a) – (b) of the Schedule 13D is amended and restated in its entirety by inserting the following information: As of the date of this Schedule 13D, ATAI AG beneficially owns 6,905,774 Ordinary Shares, representing approximately 10.1% of the 68,388,194 Ordinary Shares outstanding as of July 29, 2024. ATAI AG is a wholly owned subsidiary of ATAI N.V., and as a result, ATAI N.V. may be deemed to share beneficial ownership of the Ordinary Shares held by ATAI AG.
(c) of the Schedule 13D is hereby amended and supplemented as follows
Item 5(c) of the Schedule 13D is hereby amended and supplemented as follows: On September 26, 2024 ATAI AG sold 2,660,000 Ordinary Shares at a price of $6.05 per share in an open market transaction on the Nasdaq Global Select Market. Except for the foregoing transaction, during the past 60 days neither the Reporting Persons nor any Related Person has effected any transactions in the Ordinary Shares.
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date : September 27, 2024 ATAI LIFE SCIENCES AG By: /s/Anne Johnson Name: Anne Johnson Title: Chief Financial Officer ATAI LIFE SCIENCES N.V. By: /s/ Anne Johnson Name: Anne Johnson Title: Chief Financial Officer